In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...

A nutritionist has sounded the alarm after research revealed that millions of Brits are not getting enough of a crucial ...

Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...

The trial will explore the effects of higher doses of ACD856, building on the drug’s established safety profile.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Cambridge researchers are developing implants to help repair brain pathways damaged by Parkinson’s disease. As part of a £69 ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...